Advertisement

Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Exscientia Q&A: leveraging AI to create bispecific small molecule drugs

Creating bispecific small molecule drugs poses huge challenges, but Exscientia has successfully used AI to automate drug discovery and optimise drug design for these complex compounds. Exscientia’s CEO Andrew Hopkins discusses the importance of AI in overcoming development challenges and why targeting two targets simultaneously is efficacious in certain complex diseases.

Download our 2019 Technology, Media & Telecoms Predictions worth over $5,000 for free

Close
Close
Close

Go Top